The strong response rates in both FRα-positive and FRα-negative PROC patients position ZW191 as a potential best-in-class FRα-targeting ADC. Traders should watch for Part 2a data at a future medical meeting, which will inform dose selection and potential pivotal trial design. Given historical volatility on ZYME pipeline news, consider taking partial profits on strength.
Price Chart
Executive Summary
Zymeworks presented Phase 1 dose-escalation data for ZW191, an FRα-targeting ADC, at ESMO Gynaecological Cancers Congress 2026. The drug showed a confirmed objective response rate (cORR) of 78.6% in FRα-positive platinum-resistant ovarian cancer (PROC) patients and 47.4% in FRα-negative patients, with median progression-free survival of 7.6 months. While early-stage, the data suggests ZW191 could address limitations of current FRα-targeted therapies and broaden the treatable population, representing a positive clinical catalyst for the stock.
Key Facts
- ZW191 demonstrated a cORR of 78.6% in FRα-positive (≥75% at PS2+) PROC patients across all dose levels.
- ZW191 demonstrated a cORR of 47.4% in FRα-negative (<75% at PS2+) PROC patients across all dose levels.
- Overall cORR in PROC was 58.8% across all dose levels and 65.2% in the 6.4-9.6 mg/kg dose range.
- Median progression-free survival was 7.6 months across ovarian and endometrial cancer cohorts; median duration of response was not reached.
- Part 2a dose optimization (randomized 6.4 vs 9.6 mg/kg Q3W) has completed enrollment in ~60 PROC patients.
- Safety profile manageable: grade ≥3 TEAEs in 55% of patients, most common neutropenia (24%), anemia (20%), thrombocytopenia (12%); 20% discontinued due to AEs.
Financial Impact
Positive catalyst for ZYME stock, but magnitude uncertain given early Phase 1 data and small sample sizes. No financial figures disclosed.
Risk Factors
- Phase 1 data is early; sample sizes for subgroups not disclosed, limiting statistical reliability.
- Safety profile includes 20% discontinuation rate due to AEs; grade ≥3 neutropenia (24%) and anemia (20%) are notable.
- Competition from approved Elahere (mirvetuximab soravtansine) and other FRα-targeting ADCs in development.
- Historical ZYME bullish reports have underperformed at T+20, suggesting market skepticism toward pipeline catalysts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311472 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 8-K | $27.47 $27.50 | ▲ +0.11% | ▼ −0.87% | $25.15 (−8.45%) |
Jul 16, 2026 11w ago | Press Release | $24.19 $25.76 | ▼ −6.49% | ▼ −2.87% | $25.15 (−3.97%) |
Jun 29, 2026 13w ago | Press Release | $24.10 $22.86 | ▼ −5.15% | ▼ −4.87% | $25.15 (+4.36%) |
Jun 14, 2026 15w ago | Press Release | $23.26 $24.94 | ▲ +7.22% | ▲ +7.97% | $25.15 (+8.13%) |
May 15, 2026 19w ago | 3 | $24.43 $22.49 | ▼ −7.94% | ▼ −9.52% | $25.15 (+2.95%) |
Apr 21, 2026 23w ago | Press Release | $28.53 $24.40 | ▼ −14.48% | ▼ −17.64% | $25.15 (−11.85%) |
Apr 17, 2026 24w ago | Press Release | $27.80 $23.96 | ▼ −13.81% | ▼ −19.18% | $25.15 (−9.53%) |
Apr 16, 2026 24w ago | Press Release | $27.20 $24.57 | ▼ −9.67% | ▼ −15.48% | $25.15 (−7.54%) |
Apr 10, 2026 25w ago | 3 | $26.17 $24.03 | ▼ −8.18% | ▼ −15.91% | $25.15 (−3.90%) |
Mar 17, 2026 28w ago | Press Release | $23.45 $27.20 | ▲ +15.99% | ▲ +9.94% | $25.15 (+7.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access